Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT04047797 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Administratively Complete 75%\<Participants

Conditions

Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma

Interventions

DRUG: Ixazomib
DRUG: Ixazomib Citrate
BIOLOGICAL: Rituximab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]